|Videos|January 23, 2023
Available Adjuvant Therapy Options After Cystectomy for Patients with Stage II or III MIBC
Author(s)Matthew Galsky, MD
Dr Matthew Galsky reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
4
Durability of PFS and OS Benefit vs. Historical Control
5